Pliant Therapeutics(PLRX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from INTEGRIS-PSC 320 mg dose group demonstrated bexotegrast was well tolerated with continued antifibrotic and anti-cholestatic activity observed at 24 weeks across multiple measures BEACON-IPF Phase ...